|
gptkbp:instanceOf
|
class of antidepressant medications
|
|
gptkbp:approvedBy
|
1990s
|
|
gptkbp:cause
|
anxiety
constipation
fatigue
headache
loss of appetite
tremor
blurred vision
increased heart rate
restlessness
sweating
hyponatremia
agitation
elevated blood pressure
urinary retention
sexual dysfunction
liver enzyme elevation
increased risk of bleeding
mild increase in cholesterol
weight changes
|
|
gptkbp:contraindication
|
uncontrolled narrow-angle glaucoma
|
|
gptkbp:differenceFromSSRIs
|
also inhibit norepinephrine reuptake
|
|
gptkbp:example
|
gptkb:venlafaxine
gptkb:desvenlafaxine
gptkb:levomilnacipran
gptkb:milnacipran
gptkb:duloxetine
|
|
gptkbp:excretion
|
kidneys
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SNRIs
|
|
gptkbp:mechanismOfAction
|
inhibit reuptake of serotonin and norepinephrine
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
gptkb:MAO_inhibitors
|
|
gptkbp:pregnancyCategory
|
varies by drug
|
|
gptkbp:prescribes
|
psychiatrists
primary care physicians
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
hypertension
withdrawal symptoms on abrupt discontinuation
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
insomnia
dry mouth
increased sweating
|
|
gptkbp:standsFor
|
gptkb:Serotonin-Norepinephrine_Reuptake_Inhibitors
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:panic_disorder
gptkb:major_depressive_disorder
chronic pain
|
|
gptkbp:bfsParent
|
gptkb:fluvoxamine
gptkb:monoamine_oxidase_inhibitors
gptkb:serotonin_syndrome
|
|
gptkbp:bfsLayer
|
6
|